# Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma

> **NCT04143984** · PHASE2 · UNKNOWN · sponsor: **Shanghai Proton and Heavy Ion Center** · enrollment: 146 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Induction chemotherapy
- **RADIATION:** Carbon-ion radiotherapy
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04143984
- **Lead sponsor:** Shanghai Proton and Heavy Ion Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-19
- **Primary completion:** 2025-12-20
- **Final completion:** 2025-12-20
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143984, "Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04143984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*